Tracking tumor resistance using ‘liquid biopsies’

Luis A. Diaz, Kornelia Polyak

Research output: Contribution to journalArticlepeer-review

Abstract

Cancers are known to evolve in response to therapy, which may result in drug resistance. However, following this process in patients is challenging, as repeated biopsies of tumor tissue involves invasive procedures and tumor heterogeneity confounds interpretation of analyses. A recent study by Murtaza et al.1 describes an approach to trace the genomic evolution of tumors in response to therapy by sampling circulating cell-free tumor DNA (ctDNA) from patient plasma at different time points during treatment. This strategy allowed the authors to detect mutations associated with therapy resistance. We asked three experts to comment on this study and its implications for studying and treating tumors in the clinic.

Original languageEnglish (US)
Pages (from-to)676-677
Number of pages2
JournalNature medicine
Volume19
Issue number6
DOIs
StatePublished - Jun 2013

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Tracking tumor resistance using ‘liquid biopsies’'. Together they form a unique fingerprint.

Cite this